H. Lundbeck, Memantine - Ebixa® - approved for treatment of Alzheimer’s disease

On the meeting of 20 February 2002 the Committee for Proprietary Medicinal Products (CPMP) recommended to the EU commission to approve memantine for the treatment of moderately severe to severe Alzheimer’s disease. Marketing authorisation covering the EU is expected late first half 2002, and Lundbeck will launch memantine under the brand name Ebixa® during the second half of 2002.